Giannis Mountzios and Tony Mok
Jun 3, 2025, 04:32
Giannis Mountzios: Tony Mok Presented Herthena – Lung 03 With Patritumab DXd vs PBC in EGFR Mutation NSCLC at ASCO25
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“Tony Mok presenting Herthena -Lung 03 with patritumab DXd vs PBC in patients with EGFR mutation NSCLC
Modest PFS benefit HR=0.77, mPFS 5,8 vs 5.4
ORR 35.2 vs 25.3, including CNS ( NS)
No OS benefit
ILD=5.2%”
More posts featuring Giannis Mountzios.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41